APEIRON to Present at the Biotech Showcase™ Annual Conference 2018

APEIRON Biologics AG today announced that it will present at Biotech Showcase™ 2018, to be held January 8–10 at the Hilton San Francisco Union Square during one of the most important weeks in healthcare investing. Press release Presseaussendung

January 5, 2018
View the Post

Apeiron Announces Publication of Clinical Data with Anti-GD2 Antibody Demonstrating Efficacy in Relapsed & Refractory High-Risk Neuroblastoma

APEIRON Biologics AG today announced the publication of a successful clinical study in high-risk neuroblastoma patients in the December issue of mAbs, a prominent journal in the monoclonal antibody field. Press release Presseaussendung

December 18, 2017
View the Post

APEIRON Strengthens Management Board with Industry Expert Peter Llewellyn-Davies as New Chief Financial Officer

APEIRON Biologics AG appointed Peter Llewellyn-Davies as new Chief Financial Officer and Chief Business Officer. The biotech and financial expert Llewellyn-Davies is considered an internationally experienced and recognized transaction specialist. After marketing approval of APEIRON’s immunotherapeutic against neuroblastoma the appointment of this strategically important role should prepare the company for its next phase of growth….

October 13, 2017
View the Post